After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

We recently published 10 Big Names With Explosive Growth. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best performers on Wednesday. Recursion Pharmaceuticals jumped by 16.44 percent on ...

Recent discussions on X about Recursion Pharmaceuticals (RXRX) have centered around the company's notable stock price surge of 14% over the past month, a performance that stands out against a ...

Recursion said today it is eliminating approximately 20% of its workforce—about 160 jobs—in a restructuring the AI-based drug developer said reflects both its recently-pruned pipeline and the ...

Wildlife experts believe that predators native to the Everglades are beginning to fight back against the invasive species of snake. When you purchase through links on our site, we may earn an ...

But suddenly, it’s all looking like spaghetti. Let me introduce you to your new best friend: Frame. It helps you keep your layout neat and organized—just like folders on your desktop.